Literature DB >> 17459908

S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance.

Patrick Most1, Andrew Remppis, Sven T Pleger, Hugo A Katus, Walter J Koch.   

Abstract

Here we review the considerable body of evidence that has accumulated to support the notion of S100A1, a cardiac-specific Ca(2+)-sensor protein of the EF-hand type, as a physiological regulator of excitation-contraction coupling and inotropic reserve mechanisms in the mammalian heart. In particular, molecular mechanisms will be discussed conveying the Ca(2+)-dependent inotropic actions of S100A1 protein in cardiomyocytes occurring independently of beta-adrenergic signaling. Moreover, we will shed light on the molecular structure-function relationship of S100A1 with its cardiac target proteins at the sarcoplasmic reticulum, the sarcomere, and the mitochondria. Furthermore, pathophysiological consequences of disturbed S100A1 protein expression on altered Ca(2+) handling and intertwined systems in failing myocardium will be highlighted. Subsequently, therapeutic options by means of genetic manipulation of cardiac S100A1 expression will be discussed, aiming to complete our current understanding of the role of S100A1 in diseased myocardium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459908     DOI: 10.1152/ajpregu.00075.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  31 in total

1.  S100A1 promotes action potential-initiated calcium release flux and force production in skeletal muscle.

Authors:  Benjamin L Prosser; Erick O Hernández-Ochoa; Richard M Lovering; Zoita Andronache; Danna B Zimmer; Werner Melzer; Martin F Schneider
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-04       Impact factor: 4.249

Review 2.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

3.  The Qgamma component of intra-membrane charge movement is present in mammalian muscle fibres, but suppressed in the absence of S100A1.

Authors:  Benjamin L Prosser; Erick O Hernández-Ochoa; Danna B Zimmer; Martin F Schneider
Journal:  J Physiol       Date:  2009-08-03       Impact factor: 5.182

4.  Augmentation of Cav1 channel current and action potential duration after uptake of S100A1 in sympathetic ganglion neurons.

Authors:  Erick O Hernández-Ochoa; Benjamin L Prosser; Nathan T Wright; Minerva Contreras; David J Weber; Martin F Schneider
Journal:  Am J Physiol Cell Physiol       Date:  2009-08-05       Impact factor: 4.249

Review 5.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 6.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

Review 7.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

Review 8.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 9.  S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function.

Authors:  Mirko Völkers; David Rohde; Chelain Goodman; Patrick Most
Journal:  J Biomed Biotechnol       Date:  2010-03-28

Review 10.  S100A1: a multifaceted therapeutic target in cardiovascular disease.

Authors:  David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A Katus; Thomas G Parker; Patrick Most
Journal:  J Cardiovasc Transl Res       Date:  2010-07-20       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.